{"id":9216,"date":"2025-07-22T07:10:15","date_gmt":"2025-07-22T12:10:15","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=9216"},"modified":"2025-07-23T18:30:25","modified_gmt":"2025-07-23T23:30:25","slug":"nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/","title":{"rendered":"Nanoscope Therapeutics publica detalles sobre el mecanismo de acci\u00f3n de su tecnolog\u00eda patentada de opsina multicaracter\u00edstica de banda ancha y alta velocidad."},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

New research paper highlights the unique structure and function of Nanoscope’s synthetic opsin, supporting its potential in vision restoration<\/h3>\n

DALLAS<\/span><\/span>,\u00a022 de julio de 2025<\/span><\/span>\u00a0\u2014\u00a0Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de nuevas terapias g\u00e9nicas para pacientes que sufren p\u00e9rdida de visi\u00f3n debido a enfermedades degenerativas de la retina, anunci\u00f3 hoy la publicaci\u00f3n de un art\u00edculo\u00a0“<\/b>Topology and Mechanism of Broadband and Fast Multi-Characteristic Opsin (MCO) for Neuromodulation,”<\/b><\/a>\u00a0en\u00a0Terapias avanzadas,\u00a0<\/i>a peer-reviewed journal in Wiley’s prestigious\u00a0Avanzado<\/i>\u00a0portfolio, known for showcasing high impact biomedical research. The paper details the biophysical characteristics of Nanoscope’s proprietary therapeutic approach, MCO, including its unique structure and function, which utilizes a combination of predictive protein modeling, molecular assays, and electrophysiology.<\/p>\n

The paper highlights Nanoscope’s groundbreaking research that supports the impact observed in patients treated with the company’s lead asset therapy, MCO-010. The findings lay the groundwork to further advance this technology to help individuals affected by a range of vision loss due to retinal degenerative diseases. Functional studies using electrical recordings demonstrated that MCO is activated by ambient light, exhibits fast on-off kinetics with high photosensitivity, and maintains a broad dynamic range across the visible spectrum, enabling robust, best-in-class light-activation of MCO-expressing cells.<\/p>\n

“The highly efficient mechanism of action of our ambient light-activatable MCO stems\u00a0from\u00a0its unique structure, which allows broadband light sensitivity combined with fast channel kinetics,” said\u00a0Dr.\u00a0Samarendra Mohanty<\/span>, President & Chief Scientific Officer<\/a>\u00a0at Nanoscope and lead author of the paper. “Based on this research and multiple clinical studies, a rolling submission was\u00a0Recientemente se inici\u00f3 una solicitud de licencia para productos biol\u00f3gicos ante la FDA para MCO-010.<\/a>, with the potential to be the first gene-agnostic therapy to treat retinitis pigmentosa.”<\/p>\n

Las propiedades topol\u00f3gicas y de activaci\u00f3n funcional \u00fanicas de la prote\u00edna MCO fusionada representan hallazgos novedosos que vinculan la eficacia in vitro e in vivo de esta opsina, fundamental para la neuromodulaci\u00f3n destinada a restaurar la visi\u00f3n en pacientes con enfermedades degenerativas de la retina.<\/p>\n

Dr.\u00a0Ione Fine<\/span>, Profesor, Departamento de Psicolog\u00eda en la\u00a0Universidad de Washington<\/span><\/a>,\u00a0seattle<\/span>, commented, “The paper provides a comprehensive comparison of the performance of MCO with other opsins in development for treating retinal degenerative diseases. As such, it provides critical insights to support computational modeling for predicting sight recovery in patients treated with MCO and other opsins.”<\/p>\n

Haga clic aqu\u00ed para acceder al art\u00edculo publicado.<\/a><\/p>\n

Acerca de Nanoscope Therapeutics Inc.
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica independiente del gen para restaurar la visi\u00f3n en millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b para la retinosis pigmentaria (RP), este estudio ha comenzado a desarrollar una terapia optogen\u00e9tica que restaura la visi\u00f3n y que no depende del gen. (NCT04945772)<\/a>, la compa\u00f1\u00eda anunci\u00f3 su plan para iniciar un\u00a0Presentaci\u00f3n de BLA para MCO-010 para tratar RP<\/a>. De ser aprobado, MCO-010 podr\u00eda convertirse en el tratamiento est\u00e1ndar para pacientes con retinosis pigmentaria (RP), administr\u00e1ndose como una inyecci\u00f3n intrav\u00edtrea \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de la terapia con MCO-010 en la enfermedad de Stargardt (ES). (NCT05417126)<\/a> y planes para iniciar un\u00a0Ensayo de registro de fase 3<\/a>\u00a0En 2025, MCO-010 recibi\u00f3 la designaci\u00f3n de v\u00eda r\u00e1pida de la FDA y la designaci\u00f3n de medicamento hu\u00e9rfano para RP y SD. Los programas precl\u00ednicos incluyen la amaurosis cong\u00e9nita de Leber (LCA), en estudios precl\u00ednicos, as\u00ed como un f\u00e1rmaco listo para la solicitud de IND para la atrofia geogr\u00e1fica (GA).<\/p>\n

Contacto de inversores:<\/b>
Terap\u00e9utica del nanoscopio
(817) 857-1186
PR@nanostherapeutics.com<\/a><\/p>\n

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

New research paper highlights the unique structure and function of Nanoscope’s synthetic opsin, supporting its potential in vision restoration DALLAS,\u00a0July 22, 2025\u00a0—\u00a0Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene therapies for patients suffering vision loss from retinal degenerative diseases, today announced the publication of a paper\u00a0“Topology and Mechanism of Broadband […]<\/p>\n","protected":false},"author":6,"featured_media":9217,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-9216","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-22T12:10:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-23T23:30:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology\",\"datePublished\":\"2025-07-22T12:10:15+00:00\",\"dateModified\":\"2025-07-23T23:30:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/\"},\"wordCount\":559,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MCO-PublicationFIN.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/\",\"name\":\"Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MCO-PublicationFIN.jpg\",\"datePublished\":\"2025-07-22T12:10:15+00:00\",\"dateModified\":\"2025-07-23T23:30:25+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MCO-PublicationFIN.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MCO-PublicationFIN.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/22\\\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics publica detalles sobre el mecanismo de acci\u00f3n de su tecnolog\u00eda patentada de opsina multicaracter\u00edstica de banda ancha y alta velocidad - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-07-22T12:10:15+00:00","article_modified_time":"2025-07-23T23:30:25+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology","datePublished":"2025-07-22T12:10:15+00:00","dateModified":"2025-07-23T23:30:25+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/"},"wordCount":559,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MCO-PublicationFIN.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/","url":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/","name":"Nanoscope Therapeutics publica detalles sobre el mecanismo de acci\u00f3n de su tecnolog\u00eda patentada de opsina multicaracter\u00edstica de banda ancha y alta velocidad - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MCO-PublicationFIN.jpg","datePublished":"2025-07-22T12:10:15+00:00","dateModified":"2025-07-23T23:30:25+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MCO-PublicationFIN.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MCO-PublicationFIN.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/22\/nanoscope-therapeutics-publishes-mechanism-of-action-details-for-proprietary-broadband-and-fast-multi-characteristic-opsin-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=9216"}],"version-history":[{"count":7,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9216\/revisions"}],"predecessor-version":[{"id":9225,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9216\/revisions\/9225"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/9217"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=9216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=9216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=9216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}